SCHEMBL25210239

SCHEMBL25210239

Cn1nnc2cc([N+](=O)[O-])c(Cl)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGK1 P00558 1/20 0.44
▸ BRD4 O60885 1/20 0.42
▸ LMNA P02545 4/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ NSD2 O96028 2/20 0.41
▸ HCAR3 P49019 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ VCAM1 P19320 1/20 0.37
▸ HSD11B1 P28845 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27647530 0.83 NSD2 (0.44) BRD4LMNAALDH1A1NSD2HCAR3
SCHEMBL10347618 0.81 PGK1 (0.41) PGK1BRD4LMNAALDH1A1TSHR
SCHEMBL19848287 0.77 KEAP1 (0.47) HCAR3MAPTKDM4EMEN1KMT2A
SCHEMBL9180125 0.73 TSHR (0.62) PGK1ALDH1A1TSHRMAPK1CYP3A4
SCHEMBL25556243 0.73 KEAP1 (0.47) HCAR3MAPTKDM4EMEN1KMT2A
SCHEMBL24715163 0.72 PGK1 (0.44) PGK1LMNAALDH1A1TSHRMAPK1
SCHEMBL25221496 0.71 KEAP1 (0.41) PGK1LMNAALDH1A1HCAR3MAPT
SCHEMBL922709 0.71 NSD2 (0.61) LMNAALDH1A1NSD2CYP3A4MAPT
SCHEMBL210082 0.71 NSD2 (0.61) BRD4LMNAALDH1A1NSD2HCAR3
SCHEMBL15005983 0.70 MAPT (0.59) LMNAALDH1A1TSHRMAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 — — EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 PGK1 61/4885BRD4 585/4885LMNA 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback